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Abstract
Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell
lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL). With
notable exceptions such as ALK+ anaplastic large cell lymphoma (ALCL, ALK+), the molecular abnormalities in PTCL remain
poorly characterised. We had previously identified circulating antibodies to ALK in patients with ALCL, ALK+. Thus, as a
strategy to identify potential antigens associated with the pathogenesis of PTCL, not otherwise specified (PTCL, NOS), we
screened a testis cDNA library with sera from four PTCL, NOS patients using the SEREX (serological analysis of recombinant
cDNA expression libraries) technique. We identified nine PTCL, NOS-associated antigens whose immunological reactivity
was further investigated using sera from 52 B- and T-cell lymphoma patients and 17 normal controls. The centrosomal
protein CEP250 was specifically recognised by patients sera and showed increased protein expression in cell lines derived
from T-cell versus B-cell malignancies. TCEB3, BECN1, and two previously uncharacterised proteins, c14orf93 and ZBTB44,
were preferentially recognised by patients’ sera. Transcripts for all nine genes were identified in 39 cancer cell lines and the
five genes encoding preferentially lymphoma-recognised antigens were widely expressed in normal tissues and
mononuclear cell subsets. In summary, this study identifies novel molecules that are immunologically recognised in vivo
by patients with PTCL, NOS. Future studies are needed to determine whether these tumor antigens play a role in the
pathogenesis of PTCL.
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Introduction
Peripheral T-cell lymphomas (PTCL) are relatively uncommon,
and together with NK-cell neoplasms, comprise approximately
12% of all non-Hodgkin lymphomas (NHL) [1]. Because of
the lack of consistent immunophenotypic and genetic markers,
approximately 30% of these tumours are classified into a category
described as ‘‘not otherwise specified’’ (PTCL, NOS) in the
current World Health Organisation classification scheme [2]. In
Western countries nodal tumours are the most common form and
include three main subtypes: PTCL, NOS, angioimmunoblastic
T-cell lymphoma (AITL), and anaplastic large cell lymphoma
(ALCL), anaplastic lymphoma kinase (ALK)-positive (ALCL,
ALK+) [3]. PTCL generally express T-cell associated markers,
with nodal tumours most often being CD4+ and extranodal cases
being CD8+. However, in approximately half of cases these two
antigens are either both absent or are co-expressed [4].
The molecular abnormalities underlying PTCL are generally
poorly understood, and in contrast to data from patients with B-
NHL, reports are relatively rare. While complex and recurrent
cytogenetic abnormalities have been described, specific genetic
alterations remain elusive and have not been correlated with
histologic subgroup or clinical outcome [5]. The notable exception
is ALCL, ALK+ which express a variety of oncogenic ALK fusion
proteins [6,7] and are routinely identified as a specific entity using
an anti-ALK monoclonal antibody (ALK1) [8].
Gene expression profiling has made an important contribution
to the molecular classification of distinct disease entities and
subtypes within B-cell NHL, providing information that impacts
on both diagnosis and treatment (reviewed by [9]). Initial
expression profiling studies of nodal PTCL revealed differences
between T-cell lymphomas and normal T lymphocytes and also
molecular heterogeneity, particularly in PTCL, NOS. It was,
however, difficult to separate ALCL, ALK+, AITL and PTCL,
NOS, and to assess the contribution of reactive cells within the
tumour microenvironment [10]. More recently this approach has
suggested that AITL may be derived from follicular helper T cells
that are normally present in germinal centres and that a subset of
CD30-negative PTCL, NOS may derive from or be related to
AITL [11,12]; while the remaining PTCL, NOS are most closely
related to activated peripheral T lymphocytes [13]. More recently,
the proliferation signature has been identified as being of
importance in nodal PTCL [14] and new potential therapeutic
targets, such as PDGFRa, have been identified [13].
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As a group, PTCL are clinically aggressive and have a worse
prognosis than B-cell lymphomas when treated with chemotherapy.
Notably the T-cell immunophenotype itself is regarded as a poor
prognostic factor in studies of NHL [15]. This poor response to
therapy confers a correspondingly shorter 5-year overall survival
rate, which can be as low as 21% for patients with a high-to-
intermediate IPI (International Prognostic Index) score or 6% for
those with high-risk disease [16]. An exception to this general rule is
ALCL, ALK+ in which the majority of patients have a relatively
good prognosis [17]. Because of the dismal prognosis in PTCL,
NOS there are a variety of new experimental approaches to
treatment being investigated [18] and data suggest that high-dose
chemotherapy and autologous stem cell transplantation as a
frontline consolidation therapy may improve treatment outcome
[19].
The future development of immunotherapeutic options may
also help to improve the outcome for PTCL patients. Immuno-
therapeutic approaches using monoclonal antibodies such as
Alemtuzumab (anti-CD52) and Ontak (denileukin diftitox, anti-
CD25) are already showing promise in these malignancies [18].
Lymphoma vaccination may also have a role in the treatment of
PTCL. However, this approach requires both the identification
and characterisation of antigenic tumour proteins. We have
already demonstrated that ALCL, ALK+ patients mount both
humoral and cellular immune responses to the ALK protein and
that this may be predictive of outcome [20,21,22]. Thus cir-
culating antibodies in T-cell lymphoma patients can be raised to
molecules that play an essential role in disease pathology. The
SEREX technique (serological analysis of recombinant cDNA
expression libraries) identifies antigenic tumour-associated mole-
cules that are recognised by naturally occurring circulating
antibodies from patients, and has already been successfully used
to identify cutaneous T-cell lymphoma-associated antigens [23,24,
25,26]. Here we report the identification and further characterisa-
tion of nine lymphoma-associated SEREX antigens that are
recognised by circulating antibodies in patients with PTCL, NOS.
Materials and Methods
Ethics statement
Patient samples were collected in accordance with the Declara-
tion of Helsinki and approved by the local ethics committee
(Oxfordshire REC C; Ref no. C02.354). Patients gave written
informed consent for the sample collection.
Patient samples
Patient blood samples were obtained from the Department of
Haematology, John Radcliffe Hospital, Oxford, UK. Normal
serum samples were obtained from the National Blood Service
(Bristol, UK) with appropriate age/sex matching to patient sera
where possible. CD19+, CD3+, CD27+, IgD+ and IgD2ve
peripheral blood cells were purified from pooled buffy coat
samples taken from healthy volunteers (n = 12) using immuno-
magnetic selection (Miltenyi Biotec, Germany) according to the
manufacturer’s instructions, as previously described [27]. Lym-
phocyte populations were routinely purified to .90% purity as
determined by FACS analysis. Additional resting or activated
lymphocyte or monocyte sub-populations and normal tissue
cDNA were from the respective Human MTC panels I, II or
Human Blood Fractions (BD Biosciences, Oxford, UK).
Cell culture
Cell lines were maintained in RPMI 1640 medium (Sigma
Aldrich, UK) supplemented with 10% foetal calf serum (20% for
L540 and OCI-Ly10), 2.1 mM L-Glutamine and antibiotics
(penicillin (5000 U/ml) and streptomycin (5000 mg/ml), (Invitro-
gen, Paisley, UK) in an atmosphere of 5% CO2 at 37uC. Cells
were washed in RNase-free PBS prior to mRNA or protein
extraction.
Serum preparation
Serum was harvested from total coagulated blood by centrifu-
gation and cleaned, as previously described [28], in order to
remove any bacteriophage or bacterial responsive antibodies.
Immunoscreening of cDNA library
A testis cDNA expression library (Stratagene, La Jolla, USA)
was screened using allogeneic sera as previously described
[28]. Briefly, Escherichia coli XL1-Blue MRF’ were infected with
the recombinant phage library, plated at a density of 10000–
20000 pfu per 140 mm NZY media plate, recombinant protein
expression induced with 2 mM isopropyl-b-D-1-thiogalactopyr-
anoside (IPTG) and plates incubated at 37uC overnight. Following
protein transfer onto nitrocellulose, membranes were blocked with
blocked in 5% (w/v) non-fat milk in TBS/T, (20 mM Tris,
137 mM NaCl, 0.05% Tween-20) for 1 hour and then incubated
overnight in 1/100 diluted cleaned serum. After washing in TBS/
T membranes were incubated for 1 hour with 1/5000 diluted
alkaline phosphatase-conjugated anti-human IgG (Fc fragment
specific, Pierce, Tattenhall, UK) or anti-human IgM (Sigma) and
reactive plaques were visualised with 5-bromo-4-chloro-3-indoyl
phosphate p-toluidene salt (BCIP) and p-nitroblue tetrazolium
chloride (NBT). Positively-reacting plaques were excised, phage
eluted and re-plated in order for secondary screening with the
respective sera to confirm phage reactivity. Positive plaques were
again excised and phage eluted. Phage encoding Ig were identified
by screening with IgG secondary antibody and discarded. Phage
clones were subjected to tertiary screening with multiple sera from
lymphoma patients and normal controls to assess the frequency
and specificity of their immunological recognition, as described
previously [28].
Sequence analysis of identified antigens
pBK-CMV phagemids were in vivo excised from the ZAP
Express vector using ExAssist helper phage and the E. coli XLOLR
host strain according to the manufacturer’s instructions (Strata-
gene) and DNA was purified by miniprep (Qiagen, Crawley, UK).
Cloned inserts were sequenced (MWG-Biotech, London, UK) and
data analysed using BLAST (http://www.ncbi.nlm.nih.gov), ELM
(http://elm.org.eu), PSORT II (http://psort.nibb.ac.jp), Inter-
ProScan (http://www.ebi.ac.uk/Tools/InterProScan/) and
SMART (http://smart.embl-heidelberg.de).
RNA extraction and cDNA synthesis
mRNA from cell lines (16107 cells) was extracted using mMACS
mRNA Isolation kits (Miltenyi Biotec, Bergisch Gladbach,
Germany) and treated with DNaseI (Ambion, Warrington, UK).
Total RNA was isolated from immuno-purified B cells (CD19+)
and T cells (CD3+) with Trizol (Invitrogen) as recommended by
the manufacturer and treated with DNaseI. RNA was quantified
with a Nanodrop ND-1000 UV spectrophotometer (Nanodrop
Technologies, Wilmington, USA). cDNA was synthesised at 50uC
for 60 minutes in a 20 ml reaction mix containing 100 ng mRNA
or 500 ng total RNA, 200 U SuperscriptTM III reverse transcrip-
tase, and 16 First strand buffer (Invitrogen), 500 mM dNTPs,
250 ng random hexamers, 5 mM DTT and 1 ml RNasinH
ribonuclease inhibitor (Promega, Madison, WI, USA).
SEREX Identification of PTCL Antigens
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RT-PCR
Oligonucleotide primers (MWG-Biotech) are shown in Table
S1. The integrity of cDNA templates was assessed using primers to
TBP (TATA-box binding protein) and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase). PCR reactions (20 ml) contained either
0.5 ml of 1/20 diluted cell line cDNA or 0.5 ml of the Human
MTC panels I, II and Human Blood Fractions (BD Biosciences,
Oxford, UK), 200 mM each dNTP, 1 mM each primer, 16 PCR
buffer, 1.5 mM MgCl2 and 1 U JumpStart Taq (Sigma, Gilling-
ham, UK). Cycling parameters were as follows: initial denatur-
ation (97uC, 3 min), then 30 cycles of denaturation (95uC, 60 sec),
annealing (50uC, 60 sec) and extension (72uC, 60 sec). PCR
products were resolved by 2% TBE-agarose gel electrophoresis
and cloned with the pGEMH-T Easy system (Promega) and
sequenced (MWG-Biotech) to confirm their identity.
Real-time quantitative PCR (qRT-PCR)
The mRNA transcript levels were measured using pre-designed
TaqmanH gene expression assays for PTCL, NOS antigens and
an endogenous control assay for TBP (Table S1) (Applied
Biosystems, Foster City, CA, USA). qRT-PCR was performed
on a Chromo4 Real-Time PCR detection system (Bio-Rad,
Hercules, CA, USA) in a 20 ml reaction volume containing 1 ml of
1/20 diluted cDNA, 10 ml 26 SensiMix reaction buffer
(Quantace, London, UK) and 1 ml of the appropriate 206
Taqman assay. Taqman reactions were performed in triplicate
and the mean measurement used. PTCL, NOS antigen gene
expression data was normalised to the endogenous reference TBP
[29,30] to account for differences in RNA quality and reverse
transcription efficiency (DCt=Ct
GENE
2Ct
TBP), allowing calcu-
lation of normalised gene expression (22DCt). Normalised gene
expression in B-cell or T-cell lines was related to the average DCt
from a cohort of either 6 normal CD19+ B-cell samples or 6
normal CD3+ T-cell samples (3 male, 3 female) respectively
(DDCt=average DCt
normals
2DCt
sample), thereby allowing
calculation of relative gene expression (2DDCt).
Statistical analysis
mRNA expression was compared between cell lines and control
normal samples by a two-tailed Mann-Whitney statistical test to
95% confidence, implemented in Prism (GraphPad, San Diego,
CA, USA).
Western blotting
Whole cell lysates from 16107 cells were prepared in RIPA
buffer [31] and normalised by Bradford assay (Sigma) prior to
mixing with Laemmli loading buffer [31]. 15 mg of protein extract
was resolved using 10% SDS-PAGE and blotted with a semi-dry
apparatus (GE Healthcare, Chalfont St Giles, UK) onto PVDF
membrane (Millipore, Billerica, MA, USA). Primary antibodies
were diluted 1/200 in blocking buffer (5% w/v non-fat dry milk,
16TBS, 0.1% Tween-20) unless otherwise stated and sourced as
follows: Beclin1 (D-18, Santa Cruz, CA, USA), TCEB3 (R-19 &
H-300, Santa Cruz), ODF2 (L-20 & N-20, Santa Cruz), RIF1
(ab13422, Abcam, Cambridge, UK), CEP250/c-nap1 (BD
Biosciences), BTBD15 (ZBTB44) (1/1000, Aviva Systems Biology,
San Diego, CA, USA), and RBPJ (D-20, Santa Cruz). Antigen/
antibody complexes were detected using the relevant secondary
antibody conjugated to horseradish peroxidase (HRP) (Dako,
Glostrup, Denmark) and detected with ECL reagent (GE
Healthcare). Western blots were stripped where applicable with
Restore western blot stripping buffer (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions and re-probed as
above using loading control antibodies to GAPDH (1/1000
ab9485, Abcam) or TBP (1/2000, ab818, Abcam).
Results
Serological identification and sequence analysis of PTCL,
NOS-associated antigens
A testis library was screened using the SEREX technique with
pooled sera from four patients with PTCL, NOS to increase the
likelihood of identifying cancer testis antigens. The clinical details
of the patients whose sera were used for library screening are as
described (Table S1). Cancer testis antigens represent particularly
attractive candidates for immunotherapy because of their wide-
spread neoplastic expression and restricted normal tissue distribu-
tion [32]. Nineteen non-Ig clones were identified and validated
by secondary screening. Sequence analyses showed that these
encoded nine distinct antigens (Table 1). Interestingly three antigens,
ODF2, CEP110 (previously known as CEP1) and CEP250 (pre-
viously known as CEP2), are centrosomal proteins while four
antigens, TCEB3 (also called Elongin A), RBPJ (previously called
RBPSUH), RIF1 and ZBTB44, have (or are postulated to have, in
the case of ZBTB44) roles associated with transcription. C14orf93
and ZBTB44 have not previously been characterised, as we did not
find any existing publications specifically describing these molecules.
C14orf93 maps to 14q11.2, which is a translocation hotspot in
T-cell lymphomas because the alpha T-cell receptor genes map to
this locus. The C14orf93 protein sequence is highly conserved
across species, having 87% identity between human and murine
proteins, which may indicate that this protein performs a
functionally important biological role. There are no obvious
functional domains predicted in the c14orf93 protein, although a
possible cysteine-rich domain was identified and a potential
nuclear localisation signal (RRKR) at aa 298 leads to a PSORTII
prediction that it might encode a nuclear protein. The greatest
similarity to another human protein was to the N-terminal region
of KANK4, a protein with a KN motif and ankyrin repeat
domains which has a role in forming actin stress fibers [33].
ZBTB44 is exceptionally highly conserved across species,
having 96% identity between the human and mouse proteins
and 87% identity between human and Xenopus. ZBTB44 has N-
terminal homology to BACH1, and also exhibits homology to the
proto-oncogene Pokemon/ZBTB7A and the BTB protein
KLHL12. ZBTB44 has an N-terminal BTB/POZ domain (aa
22–128) that may mediate homo- or hetero-dimerisation [34], four
C-terminal C2H2 zinc fingers (aa 399–421, 427–449, 455–479,
487–511) and a nuclear localisation signal, suggesting a likely role
in regulating gene expression as a transcription factor.
Frequency of immunological recognition by lymphoma
patients and healthy individuals
To assess the specificity and frequency of the humoural immune
responses to these antigens, tertiary screening was performed using
69 sera from nine patients with PTCL, NOS, 15 patients with
other T-cell/NK malignancies, 28 patients with B-cell malignan-
cies and 17 normal controls (Table 2). CEP250 was the only
antigen that was recognised specifically by patients’ but not control
sera, showing reactivity with 33% of PTCL, NOS and 23% of B-
and T-NHL sera (Figure 1). Four antigens, TCEB3, BECN1,
c14orf93, and ZBTB44, showed more frequent recognition by
lymphoma patients’ sera. Of these, only BECN1 was recognised
equally frequently by patients with B- and T-cell malignancies, the
remaining antigens being more frequently recognised by sera from
patients with T-cell malignancies. ZBTB44 exhibited the highest
frequency of patient specific recognition and was recognised by
SEREX Identification of PTCL Antigens
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Table 1. Sequence and functional information for antigens identified in this study.
Antigen Frequency NCBI accession Location
SEREX database antigen ID (and
reactivity-shown in bold font)* IgG/IgM Putative/known function
TCEB3 1 NM_003198 1p36.1 NGO-Co-21 (Colon cancer);NY-SAR-20
(NK/T-cell malignant sarcoma)
IgG General transcriptional
elongation factor for RNA
polymerase II
BECN1 2 NM_003766 17q21 - IgG Autophagy; possible tumour
suppressor
c14orf93 2 NM_021944 14q11.2 - IgG N-terminal signal peptide,
possibly secreted
ODF2 1 NM_002540 9q34.11 HOM-Ts-PMR2-69 (Rhematoid arthritis
(2/19 arthritis; 0/12 healthy
controls);MO-TES-301 (Colon cancer)
IgM Component of sperm tail
cytoskeleton; possible
component of centrosomal
scaffold in somatic cells
CEP110 1 NM_007018NM_153437 9q33-q34 9; MO-TES-250 (Colon cancer);MO-
TES-258 (Colon cancer);MO-TES-385
(Colon cancer);NGO-St-64 (Stomach
cancer (1/13 stomach cancer;
1/16 healthy controls))
IgG Colocalises with CEP250 in
the pericentriolar material of
the centrosome; role in
centrosome duplication
CEP250 1 NM_007186 NM_007018 20q11.22-q12 10; NGO-Br-69 (Breast cancer
(6/31 breast cancer; 1/30
healthy controls))
IgG Core centrosomal protein;
substrate for NEK2 kinase
ZBTB44 3 NM_014155 11q24.3 NGO-Pr-87 (Prostate cancer) IgG Contains BTB domain and
C2H2 Zn fingers; possible
transcriptional repressor;
interacts in TGF-b signalling
pathway
RIF1 1 NM_018151 2q23.3 - IgM S-phase checkpoint,
mediated by ATM
RBPJ 7 NM_005349 NM_015874NM_
203283NM_203284
4p15.2 BRC-Co-5 (Colon cancer);MO-CO-1018
(Colon cancer);MO-CO-126 (Colon
cancer);MO-CO-226 (Colon cancer);
MO-TES-120 (Colon cancer);Mz19-54b
(Melanoma);NGO-Pr-38 (Prostate
cancer);NGO-St-1 (Stomach cancer
(7/13 stomach cancer; 6/16 healthy
controls));NY-BR-8 (breast cancer);
NY-CO-79 (Colon cancer);NY-REN -30
(Renal cancer);NY-TLU-65 (Lung cancer)
IgG Transcription repressor
mediating Notch signalling
pathway; required for T-cell
development by controlling
T- versus B-cell fate pathway
in lymphoid progenitors
*From the SEREX database (www2.licr.org/CancerImmunomeDB) and PubMed (www.ncbi.nlm.nih.gov/). Reactivity of antigens when known is shown in bold font.
doi:10.1371/journal.pone.0023916.t001
Table 2. Reactivity of antibodies present in the sera of lymphoma patients and normal control samples with the PTCL, NOS
antigens.
Antigen
PTCL,
NOS
(n=9)
ALCL,
ALK+*
(n = 11)
CTCL
(n =2)
NKT
(n=1)
T-ALL
(n =1)
FL
(n =5)
MCL
(n =5)
DLBCL
(n=5)
HL
(n=5)
MM
(n=3)
BL
(n =2)
MZL
(n =1)
MALT
(n=1)
IC
(n =1)
Cont.
(n = 17)
TCEB3 5 4 2 0 0 1 3 1 0 1 0 1 0 0 2
BECN1 2 1 1 0 0 0 2 2 1 0 0 1 0 0 1
C14orf93 4 4 2 0 0 0 2 0 2 1 0 1 1 0 2
ODF2 2 3 0 0 0 1 1 0 1 0 0 0 0 0 5
CEP110 9 7 2 1 1 4 5 3 5 2 1 1 0 1 15
CEP250 3 2 0 0 0 0 2 1 3 0 1 0 0 1 0
ZBTB44 6 3 2 0 0 1 0 1 0 1 0 1 0 0 2
RIF1 1 2 1 0 0 0 0 0 0 1 0 0 0 0 3
RBPJ 6 3 2 1 0 1 1 1 1 2 1 1 0 0 8
Numbers denote the number of sera from that disease type tested that reacted positively at least once in the triplicate analyses, Cont. = normal.
*ALCL, ALK+, anaplastic large cell lymphoma (ALK+); CTCL, cutaneous T cell lymphoma; NKT, natural killer T-cell lymphoma; T-ALL, T cell acute lymphoblastic leukaemia;
FL, follicular lymphoma; MCL, mantle cell lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; BL, Burkitt lymphoma; MZL, mantle zone lymphoma; MALT,
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue lymphoma; IC, immunocytic lymphoma.
doi:10.1371/journal.pone.0023916.t002
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antibodies in sera from 66% of PTCL, NOS patients and only
12% of control sera.
Analysis of mRNA expression of the PTCL,
NOS-associated antigens
The mRNA encoding each of the PTCL, NOS-associated
antigens was ubiquitously detected in a panel of 39 cancer cell lines
using RT-PCR (Figure 2). Two isoforms of RIF1 were detected
and these showed differential relative expression between cell lines.
Expression of the four genes encoding antigens that were
immunologically recognised by more than 30% of PTCL, NOS
patients and less frequently recognised by control sera (TCEB3,
c14orf93, CEP250 and ZBTB44) was also characterised using
quantitative real time PCR (Figure 3). CEP250 expression was
widely upregulated in lymphoma and myeloma cell lines, when
compared to levels in normal fractionated control cells. ZBTB44
and c14orf93 were differentially expressed, with ZBTB44 showing
highest expression levels in one B-NHL and two myeloma cell
lines and most frequent upregulation (5/9) in cell lines derived
from T-cell malignancies. In contrast, TCEB3 was generally down
regulated in most cell lines, with the notable exception being
particularly high level expression in three of four myeloma cell
lines.
The expression of each gene was also investigated by RT-PCR
in a panel of fractionated resting and activated peripheral blood
cells (Figure 4). TCEB3, BECN1 and c14orf93 were expressed at
comparable levels in both lymphocytes and monocytes, while the
remaining genes were preferentially expressed in both B and T
lymphocytes. There was an indication that many of the genes
showed reduced expression in response to cell activation. This
varied in the different T-cell populations for example CD4+ T-cell
activation had no affect on the expression of CEP250, RIF1, ODF2
or TCEB3, while all four genes appeared to be expressed at lower
levels in activated when compared to resting CD8+ T cells.
Although these cDNA panels were supplied as semi-quantitative,
via normalisation to a range of house keeping genes, there was
differing expression of the TBP gene used as a loading control.
Thus, the expression of the four genes encoding antigens that were
immunologically recognised by more than 30% of PTCL, NOS
patients (TCEB3, c14orf93, CEP250 and ZBTB44) and less
frequently recognised by control sera was also investigated in these
samples using quantitative real time PCR (Figure S1). The
expression of c14orf93 was unaffected by activation in CD14+
monocytes or CD8+ T cells, but was reduced in activated CD19+
B cells and activated CD4+ T cells. In contrast, ZBTB44 expres-
sion was decreased in activated CD4+, CD8+ and CD14+ cells but
was slightly increased in activated CD19+ B cells. All four genes
demonstrated variable responses to activation suggesting that the
regulation of these genes is affected by the cell lineage.
The expression of these genes was also investigated in seven
other normal human tissues (Figure S2). RIF1 was also included to
determine whether the two isoforms were differentially expressed
amongst normal tissues. All four genes were expressed in non-
malignant tissues from brain, colon, ovary, placenta, testis, thymus
and leukocytes. Brain and leukocytes expressed relatively low
amounts of the smaller RIF1 isoform when compared to other
normal tissues.
Analysis of protein expression of the PTCL,
NOS-associated antigens
Antibodies were commercially available to five of the nine
PTCL, NOS SEREX antigens. All the antibodies detected a
protein with a molecular weight consistent with that predicted for
the antigen. Consistent with mRNA expression data, all of the
antigens were widely expressed amongst cell lines derived from
haematological malignancies (Figure 5). Particularly interesting
was the differential expression observed for TCEB3, BECN1 and
ZBTB44 in both B and T-cell derived cell lines. CEP250 appeared
to be more highly expressed in T-cell malignancies. The anti-
ZBTB44 antibody detected an additional lower molecular weight
Figure 1. Immunoreactivity of the PTCL, NOS-associated antigens with sera from patients with PTCL, NOS (n=9), T-NHL (n=15),
B-NHL (n=32) or healthy controls (n=17).
doi:10.1371/journal.pone.0023916.g001
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protein in the two germinal centre-derived NHL cell lines, this is
most likely to represent the detection of an additional ZBTB44
isoform that is expressed in these cells.
Discussion
Using the SEREX technique we have identified nine antigens
that are immunologically recognised by autoantibodies from
patients with PTCL, NOS. Four antigens, ODF2, CEP110, RIF1
and RBPJ are also frequently recognised by antibodies in sera taken
from healthy control individuals. These represent autoantigens
whose immunological recognition is not specifically associated with
the presence of lymphoma. Our analysis of the mRNA expression of
the remaining five genes, which are preferentially recognised by sera
from lymphoma patients, suggests that all are widely expressed in
normal tissues. Thus these antigens are unlikely to represent good
candidates for lymphoma vaccination, as there may be unwanted
side effects on normal somatic tissues. However, this does not
exclude the possibility that the five antigens preferentially
recognised by sera from patients (TCEB3, BECN1, CEP250,
c14orf93 and ZBTB44) may have a role in the pathobiology of
lymphoma. Two of the antigens were previously uncharacterised,
and with the exception of BECN1 (see below), none have been
previously studied in the context of lymphoma.
Six of the identified antigens have been shown to be
immunologically recognized by cancer patient sera in previous
SEREX studies (Table 1), although none of them in T-cell
lymphoma SEREX studies [23,24,25,26], or indeed a more recent
study that used proteomic analysis to identify T-cell lymphoma-
associated antigens [35]. This is not perhaps surprising as the
current study is the first to identify PTCL, NOS-associated
SEREX antigens, whereas the other studies investigated sera from
cutaneous T-cell lymphoma patients.
CEP250 is a centrosomal protein and was the only antigen
specifically recognised by sera from lymphoma patients. At the
mRNA level, CEP250 expression was upregulated in cell lines
from haematological malignancies when compared to normal
lymphocytes, and there also appeared to be more CEP250 protein
in T-cell derived cell lines. The use of antibody interference to
study CEP250 (also known as c-Nap1) function caused centrosome
splitting, indicating that this antigen may have a role in mediating
centriole-centriole cohesion [36]. Centrosome aberrations have
been commonly identified in NHL and it has been suggested that
these may contribute to the acquisition of chromosomal instability
[37]. Furthermore, many oncogenes and tumour suppressor genes
control centrosome duplication and function, and thus it has been
suggested that centrosomes might prove to be effective cancer
targets [38]. Interestingly, chromosomal instability and supernu-
merary centrosomes have been identified as precursor defects in a
mouse model of T-cell lymphoma, which suggests they may have a
role in lymphomagenesis [39]. However, although a causal link
Figure 2. RT-PCR analysis of mRNA expression levels of genes encoding PTCL, NOS-associated antigens in cancer cell lines. 2, no
reverse transcriptase negative control; +, positive control testis cDNA. TBP was included as a positive control for the quality of the cDNA.
doi:10.1371/journal.pone.0023916.g002
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has now been identified between centrosome dysfunction and
tumorigenesis in flies, there is considerable ongoing debate as to
whether the mechanism is via genomic instability or deregulation
of asymmetric cell division [40].
TCEB3 is a component of the transcription elongation factor B
(SIII) complex that regulates the rate of transcription by RNA
polymerase II [41]. Loss of Tceb3 in mice generates an embryonic
lethal phenotype and mouse embryonic fibroblasts from these
embryos display increased apoptosis and senescence-like growth
defects [42]. Also of interest is the observation that RNA poly-
merase II bypass of oxidative damage, which may contribute to
transcriptional mutagenesis and tumour progression, is regulated
by transcription elongation factors [43].
BECN1 is a haplosufficient tumour suppressor gene and Beclin+/
2 mice suffer from a high incidence of spontaneous tumours [44].
This phenotype reflects reduced levels of autophagy, which is the
Figure 3. Quantitative real time PCR analysis of genes encoding PTCL, NOS-associated antigens in cancer cell lines. Black bars
represent T-cell lines, pale grey are Classical Hodgkin Lyphoma (CHL), white are myeloma and dark grey are B-NHL. Expression was normalised to
fractionated normal CD19+ B cells for B-cell derived cell lines or fractionated normal CD3+ T cells for T-cell derived cell lines.
doi:10.1371/journal.pone.0023916.g003
Figure 4. RT-PCR analysis of PTCL, NOS SEREX antigens in fractionated peripheral blood cells. 1, resting CD4+T cells; 2, activated CD4+ T
cells; 3, resting CD8+ T cells; 4, activated CD8+ T cells; 5, resting CD19+ B cells; 6, activated CD19+ B cells; 7, resting CD14+ monocytes; 8, activated
monocytes; 9, mononuclear B and T cells; 10, positive control placenta tissue cDNA; 11, no reverse transcriptase negative control; 12, positive control
Thiel cDNA.
doi:10.1371/journal.pone.0023916.g004
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process by which cellular proteins and organelles can be used to
generate metabolic precursors to maintain cell growth under
nutrient deprivation. At the protein level it appeared that there
was less BECN1 expression in the T-cell derived cell lines when
compared to the B-cell lines. Significantly, Th2 cells become more
resistant to growth factor withdrawal-induced cell death when
autophagy is blocked via silencing BECN1 expression [45]. It has
also been reported that the failure to sustain metabolism via
autophagy may cause genomic instability and promote tumori-
genesis, thus the loss of a survival pathway may paradoxically
enhance tumour growth [46]. Interestingly, low BECN1 expres-
sion was found to be an independent indicator of poor prognostic
outcome (PFS and OS) in a recent study of 65 extranodal NKT-
cell lymphoma cases [47].
Of particular interest for future investigation are the two
previously uncharacterised genes, c14orf93 and ZBTB44, both of
which are differentially expressed in lymphoma-derived cell lines.
Both antigens are more frequently immunologically recognised by
sera from patients with T-cell malignancies and the high sequence
conservation across species suggests that they may have an
evolutionarily-conserved function. Sequence analysis of the
predicted protein products provides little information as to the
likely role of c14orf93, but identifies ZBTB44 as a zinc finger and
BTB/POZ domain protein. The proteins that share greatest
sequence similarity to ZBTB44 have roles in cancer: Bach1 acts as
a negative regulator of p53 and connects oxygen metabolism and
cellular senescence [48], while Pokemon/ZBTB7A is overex-
pressed in multiple cancers and its expression is required for the
oncogenic transformation of mouse embryonic fibroblasts [49].
Yeast-two-hybrid studies have identified binding of ZBTB44 to
components of the Smad signalling pathway, which is regulated by
members of the TGFb superfamily and can be disrupted in cancer
[50]. As a number of BTB-containing zinc finger proteins are also
implicated in thymocyte development and T-cell function [51],
ZBTB44 may potentially play a role in normal or neoplastic T cell
development at the transcriptional level, possibly as part of a
signalling effector mechanism.
In summary, we have identified a panel of antigens that are
immunologically recognised in vivo by patients with PTCL, NOS.
Several have not previously been studied in lymphoma patients
and two antigens were previously uncharacterized. Future studies
are needed to determine whether these novel tumor antigens play
a role in the pathogenesis of PTCL.
Supporting Information
Figure S1 Quantitative real time PCR analysis of genes
encoding PTCL, NOS-associated antigens in resting and
activated mononuclear cells. Black bars represent B cells,
pale grey are T cells, dark grey are CD27-positive or CD27-
negative mononuclear cells and white are monocytes. Expression
was normalised to fractionated pooled normal CD19+ B-cells (B
cells, CD27+ and CD14+ cells) or CD3+ T-cells (T-cells).
(TIF)
Figure S2 RT-PCR analysis of mRNA expression levels
of PTCL, NOS-associated antigens in normal tissues.
2ve, no reverse transcriptase negative control; +ve, positive
control testis cDNA. TBP was included as a positive control for the
quality of the cDNA.
(TIF)
Table S1 Oligonucleotides and Taqman assays used for
RT-PCR/qRT-PCR.
(DOCX)
Figure 5. Western blot analysis of antibodies to PTCL, NOS SEREX antigens against selected whole cell RIPA extracts. T-ALL, T cell
acute lymphoblastic leukaemia; ALCL, ALK+; CTCL, cutaneous T cell lymphoma; FL, follicular lymphoma; GCB, germinal centre-derived diffuse large B
cell lymphoma; ABC, activated B cell-derived diffuse large B cell lymphoma; BL, Burkitt lymphoma; MCL, mantle cell lymphoma; HL, Hodgkin
lymphoma; CML, chronic myelogenous leukaemia.
doi:10.1371/journal.pone.0023916.g005
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